Thyroid cancer is a common endocrine malignancy. There has been exciting progress in
understanding its molecular pathogenesis in recent years, as best exemplified by the …

In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Abstract The Na+/I− symporter (NIS) is the plasma membrane glycoprotein that mediates
active I− transport in the thyroid and other tissues, such as salivary glands, stomach …

The unique oncogene duet of coexisting BRAF V600E and TERT promoter mutations are
widely found to be a robust genetic background promoting human cancer aggressiveness …

The authors review anatomical, clinical characteristics and prevalence of thyroid
microcarcinoma. Diagnostic procedures and risk factors of aggressiveness at diagnosis and …

The identification of intracellular signaling cascades important for the growth and survival of
cancer cells has led to the development of targeted cancer therapeutics aimed at blocking …

The retained functionality of the sodium iodide symporter (NIS) expressed in differentiated
thyroid cancer (DTC) cells allows the further utilization of post-surgical radioactive iodine …

The prognostic value of the BRAFV600E mutation, resulting in poor clinical outcomes of
papillary thyroid carcinoma, has been generally confirmed. However, the association of …

Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–
90% of all thyroid cancers. Genetic alternations involving the mitogen-activated protein …

The aim of this study is to search for relationships between histology, radioiodine (131 I)
uptake, fluorodeoxyglucose (FDG) uptake, and disease outcome in patients with metastatic …